
Please try another search
By Sam Boughedda
Intellia Therapeutics (NASDAQ:NTLA) was lifted to Outperform from Market Perform by BMO Capital Markets analysts on Monday after the close, with them also raising the firm's price target on the stock to $57 from $54 per share.
They believe the risk-reward for the stock is "now skewed to the upside" and that the recent NTLA-2002 IND approval removed a significant overhang for NTLA.
The company's shares are up more than 6% in Tuesday's session following the comments from the BMO analysts, although it has declined over 30% in the last 12 months. This is something they took note of in their memo.
"Since the IND approval, NTLA is trading ~19% lower (vs. -8% for XBI), suggesting that the IND approval is largely underestimated. Therefore, we believe that NTLA is currently undervalued," they wrote.
The analysts believe factors such as NTLA-2001 IND approval in mid-2023, incremental updates from early programs or new partnerships, and potential positive updates on CRISPR/Cas9 litigation with Editas/Broad can be catalysts for upside in 2023.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.